In a sweeping public health intervention aimed at eliminating excessive medical costs and democratizing cancer therapy, the National Pharmaceutical Pricing Authority (NPPA) issued final implementation directives on October 24, 2026, enforcing a strict 30 percent trade margin cap across 137 critical anti-cancer medications. Following a formal gazette notification under the Drugs (Prices Control) Order, the statutory measure targets major life-saving oncology treatments—including advanced immunotherapy drugs such as Pembrolizumab, Durvalumab, and Osimertinib, alongside targeted biologics like Bevacizumab and Denosumab. Under the regulatory mandate, pharmaceutical manufacturers and healthcare institutions must publish revised price lists ensuring maximum retail prices (MRPs) fall by up to 70 percent across retail pharmacies and hospital supply chains. Health ministry officials emphasized that state drug controllers will enforce strict monitoring protocols to prevent artificial supply shortages and ensure commercial distributors adhere to the uniform margin limits across private and government hospitals. Oncology specialists, public health advocates, and patient welfare organizations widely praised the government intervention, highlighting that rationalizing cancer medicine pricing curbs predatory trade markups, prevents catastrophic medical debt, and ensures vital targeted therapies remain accessible to vulnerable families nationwide.

Extraordinary Regulatory Order Slashes High Markups on Oncology Formulations

In an effort to shield households from catastrophic out-of-pocket healthcare expenses, the National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, notified a 30% trade margin cap across 137 critical non-scheduled anti-cancer formulations.

The government exercised powers under Paragraph 19 of the Drugs (Prices Control) Order, 2013 (DPCO 2013), which allows the regulator to fix and revise medicine ceilings under extraordinary circumstances in public interest. The official gazette notification, issued on October 17, 2026, requires pharmaceutical manufacturers, stockists, and hospital pharmacies to roll out downward-revised Maximum Retail Prices (MRPs) starting November 9, 2026.

Overview: Key Parameters of NPPA's Oncology Trade Margin Rationalisation (TMR)

Regulatory & Pricing MetricDetails & Statutory Directives
Regulatory BodyNational Pharmaceutical Pricing Authority (NPPA)
Statutory Enabling ProvisionParagraph 19 of DPCO, 2013 (Public Interest Extraordinary Powers)
Covered Formulations137 Non-Scheduled Anti-Cancer Drugs
Trade Margin Cap FormulaMaximum 30% on Maximum Retail Price (MRP)
Mathematical Permissible MarkupPTS ÷ 0.70 (Allowable 42.8% markup on Price to Stockist)
Anticipated MRP ReductionUp to 70% decrease across covered therapies
Annual Patient Cost SavingsEstimated ₹2,000 to ₹2,500 Crore
Effective Nationwide ImplementationNovember 9, 2026

The Math of Margin Rationalisation: Capping Downstream Inflation

Prior to this notification, non-scheduled oncology medicines were free from statutory ceiling prices, allowing distributors and captive hospital pharmacies to levy markups ranging between 170% and over 700% above the manufacturer’s Price to Stockist (PTS).

Trade Margin Rationalisation (TMR) Flow: --------------------------------------- Manufacturer Base Cost ──> Price to Stockist (PTS) ──> Capped at Max 42.8% Markup ──> MRP Fixed at PTS ÷ 0.70 ──> Up to 70% Price Relief for Patients

Under the Trade Margin Rationalisation (TMR) formula, the maximum allowable trade margin across all wholesale and retail intermediary tiers is capped at 30% of the MRP. In operational terms, the final price is calculated by dividing the baseline PTS by 0.70, setting a statutory cap on the retail price.

The list of 137 formulations was recommended by an expert committee constituted under the Directorate General of Health Services (DGHS), comprising senior oncologists, medical specialists, and public health economists. The notified schedule encompasses vital advanced therapies, including:

  • Immunotherapies and Monoclonal Antibodies: Pembrolizumab, Durvalumab, Nivolumab, and Bevacizumab, widely prescribed across lung, colorectal, ovarian, and cervical malignancies.

  • Targeted Kinase Inhibitors: Advanced oral therapies such as Osimertinib used in non-small cell lung carcinoma.

  • Supportive & Hormone Therapies: Pegfilgrastim, which prevents severe neutropenia in chemotherapy patients, and Denosumab, used for bone metastases in breast and prostate cancers.

"Excessive trade margins captured along downstream distribution corridors and institutional pharmacies have long distorted cancer care economics. By invoking Paragraph 19, the government is ensuring that life-saving therapeutic innovations reach patients at equitable rates while preserving legitimate manufacturing returns." — Department of Pharmaceuticals Statement

Enforcement Timeline and Hospital Compliance Directives

Drug manufacturers must communicate revised price lists to the NPPA within seven days and publish updated figures on their corporate portals.

From November 9, 2026, hospital dispensaries, independent retail pharmacies, and clinical day-care centers will be legally barred from billing patients above the recalculated MRPs. Hospitals are further mandated to display the revised rate schedules on their websites and institutional notice boards.

State Drug Controllers have been directed to conduct field inspections to ensure full compliance. Concurrently, pharmaceutical companies are legally mandated under DPCO Paragraph 21(2) to maintain uninterrupted production and domestic distribution volumes to prevent artificial supply shortages. Patients and caregivers will be able to verify authentic, revised price schedules in real time using the national Pharma Sahi Daam mobile application and the central NPPA portal.